Haemostatic genetic risk factors in arterial thrombosis

Thrombosis and Haemostasis

Volumn 86, Issue 1, 2001, Pages 374-385

  Simmonds, R E ^a   Hermida, J ^a   Rezende, S M ^a   Lane, D A ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Coagulation; Fibrinolysis; Haemostatic polymorphism; Platelet membrane glycoproteins

Indexed keywords

BLOOD CLOTTING FACTOR 5; BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 8; FIBRINOGEN; FIBRINOGEN RECEPTOR; GLYCOPROTEIN IB; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEIN C; PROTHROMBIN; THROMBOMODULIN; TISSUE FACTOR PATHWAY INHIBITOR; VERY LATE ACTIVATION ANTIGEN 2;

ARTERY THROMBOSIS; BLOOD CLOTTING PARAMETERS; CONFERENCE PAPER; DISEASE ASSOCIATION; DISEASE MARKER; FIBRINOLYSIS; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC RISK; GENOTYPE; HEMOSTASIS; HUMAN; MEDICAL RESEARCH; OUTCOMES RESEARCH; PHENOTYPE; PRIORITY JOURNAL; PROPHYLAXIS; RISK ASSESSMENT; TREATMENT PLANNING;

EID: 0034916405     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1616235     Document Type: Conference Paper

References (128)

1. Role of hemostatic gene polymorphisms in venous and arterial thrombosis
2. Haemostatic function and ischaemic heart disease: Principal results of the Northwick Park Heart Study
3. Fibrinogen as a risk factor for stroke and myocardial infarction
4. Fibrinogen and factor VII in the prediction of coronary risk
5. A prospective study of fibrinogen and risk of myocardial infarction in the physicians' health study
6. Epidemiological evidence for inflammation in cardiovascular disease
7. β fibrinogen gene polymorphisms are associated with plasma fibrinogen and coronary artery disease in patients with myocardial infarction
8. Gene-environment interaction in the determination of levels of plasma fibrinogen
9. Two common, functional polymorphisms in the promoter region of the β-fibrinogen gene contribute to regulation of plasma fibrinogen concentration
10. Fibrinogen, factor VII and PAI-1 genotypes and the risk of coronary and peripheral atherosclerosis: Edinburgh artery study
11. Polymorphisms of factor V, factor VII, and fibrinogen genes. Relevance to severity of coronary artery disease
12. -455G/A polymorphism of the β-fibrinogen gene is associated with the progression of coronary atherosclerosis in symptomatic men. Proposed role for an acute phase reaction pattern of fibrinogen
13. Positive association of the β fibrinogen H1/H2 gene variation to basal fibrinogen levels and to increase in fibrinogen concentration during acute phase reaction but not to coronary artery disease and myocardial infarction
14. A common mutation (G-455 to A) in the β-fibrinogen promoter is an independent predictor of plasma fibrinogen, but not of ischemic heart disease. A study of 9,127 individuals based on the Copenhagen City Heart Study
15. -455-A β-gene) is associated with differences in plasma fibrinogen levels in young men and women from different regions in Europe. Evidence for gender-genotype-environment interaction
16. Bcl I polymorphism in the fibrinogen β-chain gene is associated with the risk of familial myocardial infarction by increasing plasma fibrinogen levels. A case-control study in a sample of GISSI-2 patients
17. Elevated plasma fibrinogen. Cause or consequences of cardiovascular disease
18. Fibrinogen polymorphisms are not associated with the risk of myocardial infarction
19. Gender-specific associations of the fibrinogen Bβ 448 polymorphism, fibrinogen levels, and acute coronary disease
20. β-fibrinogen gene polymorphism (C148 to T) is associated with carotid atherosclerosis
21. Coagulation factor VII and the risk of coronary heart disease in healthy men
22. Hemostatic factors as predictors of ischemic heart disease and stroke in the Edinburgh Artery Study
23. Modulation of factor VII levels by intron 7 polymorphisms: Population and in vitro studies
24. The Arg353Gln polymorphism reduces the level of coagulation factor VII. In vivo and in vitro studies
25. Coagulation factor VII mass and activity in young men with myocardial infarction at a young age. Role of plasma lipoproteins and factor VII genotype
26. Factor VII Arg/Gln353 polymorphism determines factor VII coagulant activity in patients with myocardial infarction (MI) and control subjects in Belfast and in France but is not a strong indication of MI risk in the ECTIM study
27. Association of factor VII:C levels with environmental and genetic factors in patients with ischaemic heart disease and coronary atheroma characterised by angiography
28. Polymorphisms in the coagulation factor VII gene and the risk of myocardial infarction
29. Prothrombotic genetic risk factors in young survivors of myocardial infarction
30. A genetic propensity to high factor VII is not associated with the risk of myocardial infarction in men
31. Polymorphisms in the factor VII gene and the risk of myocardial infarction in patients with coronary artery disease
32. Factor VII gene polymorphism, factor VII levels, and prevalent cardiovascular disease. The Framingham Heart Study
33. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction
34. Myocardial infarction, Arg 506 to Gln factor V mutation, and activated protein C resistance
35. Factor V (Arg506 to Gln) mutation in young survivors of myocardial infarction
36. Factor V Leiden is not a risk factor for arterial vascular disease in the elderly: Results from the Cardiovascular Health Study
37. G20210A mutation in prothrombin gene and risk of myocardial infarction, stroke, and venous thrombosis in a large cohort of US men
38. The heterozygous 20210 G/A prothrombin genotype is associated with early venous thrombophilias and is not increased in frequency in arterial disease
39. Factor V Leiden gene mutation and thrombin generation in relation to acute stroke
40. Risk of stroke in young women and two prothrombotic mutations: Factor V Leiden and prothrombin gene variant (G20210A)
41. Factor V Leiden (resistance to activated protein C) increases the risk of myocardial infarction in young women
42. A common prothrombin variant (20210 G to A) increases the risk of myocardial infarction in young women
43. Interaction of coagulation defects and cardiovascular risk factors. Increased risk of myocardial infarction associated with factor V Leiden or prothrombin 20210A
44. Synergistic effects of prothrombotic polymorphisms and atherogenic factors on the risk of myocardial infarction
45. Poor response to activated protein C as a prominent risk predictor of advanced arterial disease
46. Prothrombin G20210A mutant genotype is a risk factor for cerebrovascular ischemic disease in young patients
47. A factor V genetic component differing from factor V R506Q contributes to the activated protein C resistance phenotype
48. Factor V gene mutations (R2 gene) are associated with coronary artery disease in elderly people
49. The HR2 haplotype of factor V is not associated with the risk of myocardial infarction
50. Association of a common polymorphism in the factor XIII gene with myocardial infarction
51. Association of FXIII Val134Leu with decreased risk of myocardial infarction in Finnish males
52. Inhibition of factor XIIIa in a canine model of coronary thrombosis: Effect of reperfusion and acute reocclusion after recombinant tissue-type plasminogen activator
53. The contribution of activated Factor XIII to fibrinolytic resistance in experimental pulmonary embolus
54. The factor XIII V34L polymorphism accelarates thrombin activation of factor XIII and affects cross-linked fibrin structure
55. Val134Leu polymorphism of plasma factor XIII: Biochemistry and epidemiology in familial thrombophilia
56. Factor XIIIVa134Leu: A novel association with primary intracerebral haemorrhage
57. The association between the Va134Leu polymorphism in the factor XIII gene and brain infarction
58. Soluble thrombomodulin as a predictor of incident coronary heart disease and symptomless carotid artery atherosclerosis in the Atherosclerosis Risk in Communities (ARIC) Study: A case-cohort study
59. Identification and characterisation of a thrombomodulin gene mutation coding for an elongated protein in reduced expression in a kindred with reduced expresssion in a kindred with myocardial infarction
60. A novel thrombomodulin gene mutation in a patient suffering from saggital sinus thrombosis
61. A mutation in the thrombomodulin gene, 127G to A coding for Ala25Thr, and the risk of myocardial infarction
62. Thrombomodulin gene mutations associated with myocardial infarction
63. A common thrombomodulin amino acid dimorphism is associated with myocardial infarction
64. Mutations in promoter region of thrombomodulin and venous thromboembolism
65. G-33A mutation in the promoter region of thrombomodulin gene and its association with coronary artery disease and plasma soluble thrombomodulin levels
66. A 23bp insertion in the endothelial protein C receptor (EPCR) gene in patients with myocardial infarction and deep vein thrombosis
67. C-399T polymorphism in the promoter region of human tissue pathway inhibitor (TFPI) gene does not change the plasma TFPI antigen and does not cause venous thrombosis
68. Polymorphisms in the tissue factor pathway inhibitor gene (TFPI) in patients with acute coronary syndromes and in healthy subjects: Impact of the V264M substitution on plasma levels of TFPI
69. A new T-287C polymorphism in the 5′ regulatory region of the tissue factor pathway inhibitor gene. Association studies of the T-287C and C-399T polymorphisms with coronary artery disease
70. Common genetic polymorphism (46 C to T substitution) in the 5-untranslated of the coagulation factor XII gene is associated with low translation efficiency and decrease in plasma factor XII level
71. Epidemiological and genetic associations of activated factor XII concentration with factor VII activity, fibrinopeptide A concentration, and risk of coronary heart disease in men
72. Localization and production of plasminogen activator inhibitor-1 in human healthy and atherosclerotic arteries
73. Increased plasminogen activator inhibitor type 1 in coronary artery atherectomy specimens from type 2 diabetic compared with non-diabetic patients A potential factor predisposing to thrombosis and its persistence
74. Plasminogen-activator inhibitor type 1 and coronary artery disease
75. Genetic variation at the plasminogen activator inhibitor-1 locus is associated with altered levels of plasminogen activator inhibitor-1 activity
76. The two allele sequences of a common polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene respond differently to interleukin-1 in HepG2 cells
77. The 4G4G genotype of the plasminogen activator inhibitor 4G/5G gene polymorphism is associated with coronary atherosclerosis in patients at high risk for this disease
78. The PAI-1 gene locus 4G/5G polymorphism is associated with a family history of coronary artery disease
79. Allele-specific increase in basal transcription of the plasminogen-activator inhibitor 1 gene is associated with myocardial infarction
80. The 4G/5G genetic polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene is associated with differences in plasma PAI-1 activity but not with risk of myocardial infarction in the ECTIM study
81. Plasminogen activator inhibitor-1 (PAI-1) promoter 4G/5G genotype and levels in relation to a history of myocardial infarction in patients characterised by coronary angiography
82. 4G/5G promoter PAI-1 gene polymorphism is associated with plasmatic PAI-1 activity in Italians: A model of gene-environment interaction
83. Arterial and venous thrombosis is not associated with the 4G/5G polymorphism in the promoter of the plasminogen activator inhibitor gene in a large cohort of US men
84. The 4G/5G polymorphism in the plasminogen activator inhibitor-1 gene is not associated with myocardial infarction
85. Plasminogen activator inhibitor-1 4G/5G promoter polymorphism and levels in subjects with cerebrovascular disease
86. Plasminogen activator inhibitor 4G polymorphism is associated with decreased risk of cerebrovascular mortality in older women
87. Endogenous tissue-type plasminogen activator and risk of myocardial infarction
88. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris
89. Alleleic dimorphism in the human tissue-type plasminogen activator (TPA) gene as a result of an Alu insertion/deletion event
90. Alu-repeat polymorphism in the tissue-type plasminogen activator gene does not affect basal endothelial tPA synthesis
91. Tissue plasminogen activator and the risk of myocardial infarction
92. Alu-repeat polymorphism in the gene coding for tissue-type plasminogen activator (t-PA) and risks of myocardial infarction among middle-aged men
93. The 4G/5G polymorphism of PAI-1 promoter gene and the risk of myocardial infarction: A meta-analysis
94. A polymorphism of a platelet glycoprotein receptor as an inherited risk factor for coronary thrombosis
95. Association of the platelet P1(A) polymorphism of glycoprotein IIb/IIIa and the fibrinogen Bβ448 polymorphism with myocardial infarction and extent of coronary artery disease
96. P1A1/A2 polymorphism of platelet glycoprotein IIIa and risks of myocardial infarction, stroke and venous thrombosis
97. The Leu 33/Pro polymorphism (P1A1/P1A2) of the glycoprotein IIIa (GPIIIa) receptor is not related to myocardial infarction in the ECTIM Study
98. Association of the platelet glycoprotein IIIa P1A1/A2 gene polymorphism to coronary artery disease but not to nonfatal myocardial infarction in low risk patients
99. HPA-1 and HPA-3 polymorphisms of the platelet fibrinogen receptor and coronary artery disease and myocardial infarction
100. Glycoprotein IIIa PLA polymorphism associates with progression of coronary artery disease and with myocardial infarction in an autopsy series of middle-aged men who died suddenly
101. Platelet PLA2 allele and the incidence of coronary heart disease. Results from the Atherosclerosis Risk in the Communities (ARIC) study
102. Platelet glycoprotein IIIa polymorphisms and risk of coronary stent thrombosis
103. PLA polymorphism of platelet glycoprotein IIIa and risk of restonosis after coronary stent placement
104. A1/A2 polymorphism of glycoprotein IIIa and association with excess procedural risk for coronary catheter interventions: A case-controlled study
105. The PLA2 allele and cardiovascular disease: The pro33 and con
106. Polymorphism of human glycoprotein Ibα results from a variable number of tandem repeats of a 13-amino acid sequence in the mucin-like macropeptide region
107. Threonine-145/methionine-145 variants of baculovirus produced recombinant ligand binding domain of GPIbα express HPA-2 epitopes and show equal binding of von Willebrand factor
108. The largest variant of platelet glycoprotein Ibα has four tandem repeats of 13 amino acids in the macroglycopeptide region and a genetic linkage with methionine
109. Kozak sequence polymorphism of the glycoprotein (GP) Ibα gene is a major determinant of the plasma membrane levels of the platelet GP Ib-IX-V complex
110. A common polymorphism flanking the ATG initiator codon of GPIbα does not affect expression and is nt a major risk factor for arterial thrombosis
111. Coronary artery disease and polymorphisms in a receptor mediating shear stress-dependent platelet activation
112. Polymorphisms of platelet membrane glycoprotein Ibα associated with arterial thrombotic disease
113. Myocardial infarction: Absence of association with VNTR polymorphism
114. Genetic variants of platelet glycoprotein receptors and the risk of stroke in young women
115. Association between platelet glycoprotein Ibα genotype and ischemic cerebrovascular disease
116. Variability of integrin α2β1 activity on human platelets
117. Hereditary variation in platelet α2β1 density is associated with two silent polymorphisms
118. Low platelet α2β1 levels in type I von Willebrand disease correlate with impaired platelet function in a high shear stress system
119. The human platelet alloantigens Bra and Brb are associated with a single amino acid polymorphism on glycoprotein (integrin α2 subunit)
120. Association of the platelet glycoprotein Ia C807T gene polymorphism with nonfatal myocardial infarction in younger patients
121. Association of two silent polymorphisms of the platelet glycoprotein Ia/IIa receptor with risk of myocardial infarction: A case control study
122. The GPIa C807T dimorphism associated with platelet collagen receptor density is not a risk factor for myocardial infarction
123. The impact of the glycoprotein Ia collagen receptor subunit A1648G gene polymorphism on coronary artery disease and acute myocardial infarction
124. Homozygosity for 807 T polymorphism in α2 subunit of platelet α2 β1 is associated with increased risk of cardiovascular mortality in high-risk women
125. Glycoprotein Ia gene C807T polymorphism and risk for major adverse cardiac events within the first 30 days after coronary artery stenting
126. The platelet glycoprotein Ia C807T polymorphism as risk factor for coronary catheter interventions
127. The α2 gene coding sequence T807/A873 of the platelet collagen receptor integrin α2 β1 might be a genetic risk factor for the development of stroke in younger patients
128. Shattuck lecture-medical and societal consequences of the human genome project